Home
>
US Stocks
>
Inmode Ltd

Inmode Ltd (INMD)

$32.18

+0.61

(+1.93%)▲

Market is closed - opens 7 PM, 02 Jun 2023

Insights on Inmode Ltd

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 133.57M → 106.07M (in $), with an average decrease of 20.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 37.70M → 40.50M (in $), with an average increase of 6.9% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 26.6% return, outperforming this stock by 5.5%

Performance

  • $31.68
    $32.37
    $32.18
    downward going graph

    1.55%

    Downside

    Day's Volatility :2.13%

    Upside

    0.59%

    downward going graph
  • $21.20
    $41.84
    $32.18
    downward going graph

    34.12%

    Downside

    52 Weeks Volatility :49.33%

    Upside

    23.09%

    downward going graph

Returns

PeriodInmode LtdSector (Health Care)Index (Russel 2000)
3 Months
-6.59%
0.7%
-7.0%
6 Months
-14.28%
-7.9%
-6.5%
1 Year
21.11%
-2.0%
-6.8%
3 Years
107.35%
25.4%
24.7%

Highlights

Market Capitalization
2.6B
Book Value
$7.25
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
1.99
PE Ratio
15.86
PEG Ratio
2.9
Wall Street Target Price
47.0
Profit Margin
36.05%
Operating Margin TTM
42.97%
Return On Assets TTM
22.47%
Return On Equity TTM
34.0%
Revenue TTM
474.4M
Revenue Per Share TTM
5.75
Quarterly Revenue Growth YOY
23.5%
Gross Profit TTM
380.8M
EBITDA
204.6M
Diluted Eps TTM
1.99
Quarterly Earnings Growth YOY
0.31
EPS Estimate Current Year
2.63
EPS Estimate Next Year
2.99
EPS Estimate Current Quarter
0.47
EPS Estimate Next Quarter
0.65

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Inmode Ltd(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 46.05%

Current $32.18
Target $47.00

Company Financials

FY17Y/Y Change
Revenue
53.5M
↑ 131.59%
Net Income
8.8M
↑ 2524.7%
Net Profit Margin
16.5%
↑ 15.04%
FY18Y/Y Change
Revenue
100.2M
↑ 87.37%
Net Income
22.4M
↑ 153.67%
Net Profit Margin
22.33%
↑ 5.83%
FY19Y/Y Change
Revenue
156.4M
↑ 56.11%
Net Income
61.1M
↑ 173.32%
Net Profit Margin
39.11%
↑ 16.78%
FY20Y/Y Change
Revenue
206.1M
↑ 31.81%
Net Income
75.0M
↑ 22.71%
Net Profit Margin
36.4%
↓ 2.71%
FY21Y/Y Change
Revenue
357.6M
↑ 73.49%
Net Income
165.0M
↑ 119.87%
Net Profit Margin
46.14%
↑ 9.74%
FY22Y/Y Change
Revenue
454.3M
↑ 27.05%
Net Income
161.5M
↓ 2.09%
Net Profit Margin
35.56%
↓ 10.58%
Q4 FY21Q/Q Change
Revenue
110.5M
↑ 17.38%
Net Income
52.7M
↑ 17.82%
Net Profit Margin
47.66%
↑ 0.18%
Q1 FY22Q/Q Change
Revenue
85.9M
↓ 22.27%
Net Income
31.0M
↓ 41.21%
Net Profit Margin
36.05%
↓ 11.61%
Q2 FY22Q/Q Change
Revenue
113.5M
↑ 32.15%
Net Income
44.0M
↑ 42.21%
Net Profit Margin
38.79%
↑ 2.74%
Q3 FY22Q/Q Change
Revenue
121.2M
↑ 6.77%
Net Income
48.8M
↑ 10.76%
Net Profit Margin
40.24%
↑ 1.45%
Q4 FY22Q/Q Change
Revenue
133.6M
↑ 10.18%
Net Income
37.7M
↓ 22.71%
Net Profit Margin
28.23%
↓ 12.01%
Q1 FY23Q/Q Change
Revenue
106.1M
↓ 20.59%
Net Income
40.5M
↑ 7.42%
Net Profit Margin
38.19%
↑ 9.96%
FY17Y/Y Change
Total Assets
39.4M
↑ 139.22%
Total Liabilities
20.0M
↑ 170.71%
FY18Y/Y Change
Total Assets
81.1M
↑ 105.51%
Total Liabilities
36.4M
↑ 82.0%
FY19Y/Y Change
Total Assets
218.4M
↑ 169.42%
Total Liabilities
38.6M
↑ 6.05%
FY20Y/Y Change
Total Assets
295.8M
↑ 35.43%
Total Liabilities
40.3M
↑ 4.42%
FY21Y/Y Change
Total Assets
478.5M
↑ 61.8%
Total Liabilities
62.7M
↑ 55.73%
FY22Y/Y Change
Total Assets
644.4M
↑ 34.66%
Total Liabilities
89.8M
↑ 43.12%
Q4 FY21Q/Q Change
Total Assets
478.5M
↑ 6.9%
Total Liabilities
62.7M
↓ 1.4%
Q1 FY22Q/Q Change
Total Assets
464.5M
↓ 2.94%
Total Liabilities
61.1M
↓ 2.54%
Q2 FY22Q/Q Change
Total Assets
523.2M
↑ 12.65%
Total Liabilities
70.4M
↑ 15.12%
Q3 FY22Q/Q Change
Total Assets
579.0M
↑ 10.66%
Total Liabilities
70.7M
↑ 0.41%
Q4 FY22Q/Q Change
Total Assets
644.4M
↑ 11.3%
Total Liabilities
89.8M
↑ 27.04%
Q1 FY23Q/Q Change
Total Assets
669.6M
↑ 3.91%
Total Liabilities
66.6M
↓ 25.79%
FY17Y/Y Change
Operating Cash Flow
14.6M
↑ 387.62%
Investing Cash Flow
-5.7M
↑ 1234.27%
Financing Cash Flow
1.8M
↑ 3267.92%
FY18Y/Y Change
Operating Cash Flow
36.9M
↑ 152.49%
Investing Cash Flow
-29.7M
↑ 423.21%
Financing Cash Flow
186.0K
↓ 89.58%
FY19Y/Y Change
Operating Cash Flow
62.2M
↑ 68.64%
Investing Cash Flow
-112.5M
↑ 278.13%
Financing Cash Flow
70.2M
↑ 37627.42%
FY20Y/Y Change
Operating Cash Flow
79.2M
↑ 27.36%
Investing Cash Flow
-43.3M
↓ 61.49%
Financing Cash Flow
-12.4M
↓ 117.73%
FY21Y/Y Change
Operating Cash Flow
174.9M
↑ 120.74%
Investing Cash Flow
-160.1M
↑ 269.72%
Financing Cash Flow
-15.0M
↑ 20.74%
Q4 FY21Q/Q Change
Operating Cash Flow
52.9M
↑ 4.79%
Investing Cash Flow
-30.8M
↓ 36.01%
Financing Cash Flow
-22.9M
↓ 540.46%
Q1 FY22Q/Q Change
Operating Cash Flow
31.9M
↓ 39.78%
Investing Cash Flow
-2.4M
↓ 92.29%
Financing Cash Flow
-42.5M
↑ 85.45%
Q2 FY22Q/Q Change
Operating Cash Flow
47.0M
↑ 47.49%
Investing Cash Flow
-2.4M
↑ 0.0%
Financing Cash Flow
204.0K
↓ 100.48%
Q3 FY22Q/Q Change
Operating Cash Flow
45.6M
↓ 2.96%
Investing Cash Flow
-56.1M
↑ 2264.49%
Financing Cash Flow
550.0K
↑ 169.61%

Technicals Summary

Sell

Neutral

Buy

Inmode Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inmode Ltd
Inmode Ltd
-4.88%
-14.28%
21.11%
107.35%
374.28%
Stryker Corporation
Stryker Corporation
-5.21%
14.59%
18.85%
40.42%
57.95%
Boston Scientific Corp.
Boston Scientific Corp.
-2.65%
10.52%
26.63%
37.19%
68.3%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-2.94%
11.34%
-15.79%
13.9%
79.08%
Abbott Laboratories
Abbott Laboratories
-7.78%
-4.88%
-12.5%
11.01%
63.15%
Medtronic PLC
Medtronic PLC
-8.29%
3.93%
-15.99%
-14.91%
-5.45%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inmode Ltd
Inmode Ltd
15.86
15.86
2.9
2.63
0.34
0.22
0.0
7.25
Stryker Corporation
Stryker Corporation
40.11
40.11
2.85
10.16
0.16
0.06
0.01
44.51
Boston Scientific Corp.
Boston Scientific Corp.
41.35
41.35
2.53
1.95
4.89
0.04
0.0
12.42
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
35.24
35.24
3.07
2.55
0.25
0.13
0.0
9.87
Abbott Laboratories
Abbott Laboratories
24.71
24.71
18.76
4.4
16.03
0.06
0.02
21.28
Medtronic PLC
Medtronic PLC
17.98
17.98
3.04
5.28
7.81
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inmode Ltd
Inmode Ltd
Buy
$2.6B
374.28%
15.86
36.05%
Stryker Corporation
Stryker Corporation
Buy
$104.6B
57.95%
40.11
13.86%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$72.6B
68.3%
41.35
6.92%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$51.1B
79.08%
35.24
27.07%
Abbott Laboratories
Abbott Laboratories
Buy
$176.9B
63.15%
24.71
13.98%
Medtronic PLC
Medtronic PLC
Buy
$109.8B
-5.45%
17.98
12.03%

Institutional Holdings

  • Acadian Asset Management LLC

    4.17%

  • Renaissance Technologies Corp

    2.91%

  • Millennium Management LLC

    2.30%

  • BlackRock Inc

    2.26%

  • American Century Companies Inc

    1.85%

  • William Blair Investment Management, LLC

    1.81%

Company Information

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ('RF') technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology.

Organization
Inmode Ltd
Employees
480
CEO
Mr. Yair Malca
Industry
Health Technology

Discover More

FAQs